Products of vasopressin gene expression in small-cell carcinoma of the lung

• Published in: British journal of cancer Vol. 69; no. 2; pp. 260 - 263
• Main Authors: FRIEDMANN, A. S, MALOTT, K. A, MEMOLI, V. A, PAI, S. I, YU, X.-M, NORTH, W. G
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.02.1994
• Subjects: Biological and medical sciences; carcinoma; Carcinoma, Small Cell - chemistry; Carcinoma, Small Cell - genetics; gene expression; Humans; lung; Lung Neoplasms - chemistry; Lung Neoplasms - genetics; man; Medical sciences; Neurophysins - analysis; Pneumology; products; Protein Precursors - analysis; Tumors of the respiratory system and mediastinum; vasopressin; Vasopressins - analysis; Human; Immunohistochemistry; Lung disease; Respiratory disease; Peptide hormone; Exploration; Malignant tumor; Gene expression; Neuropeptide; Bronchopulmonary; Vasopressin; Pathology; Neurohypophyseal hormone; Bronchus disease; Oat cell carcinoma
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1994.49

Small-cell neuroendocrine carcinoma of the lung is known to express products related to the vasopressin gene, although these products have been reported to sometimes differ from those generated by neurones of the hypothalamo-neurohypophyseal system. To further investigate vasopressin gene expression in neuroendocrine carcinomas, we performed immunohistochemistry on 24 histologically classified small-cell carcinomas using antibodies directed against different regions of the vasopressin precursor. All of the tumours examined contained at least two parts of the vasopressin precursor, suggesting that vasopressin might have a biological role in these tumours and indicating a role for these products in tumour diagnosis and treatment. Sixty-seven per cent of the tumours contained immunoreactivity for all major regions of the precursor: vasopressin, vasopressin-associated human neurophysin, the bridging region between the hormone and the neurophysin, and vasopressin-associated human glycopeptide. However, 33% of the tumours examined appeared to express only part of the vasopressin precursor, as evidenced by the absence of immunoreactivity for the neurophysin and/or the glycopeptide. These results support the proposition that both normal and abnormal vasopressin gene expression occurs in small-cell carcinoma of the lung.